About the Market

Biologic-baseddrugs are an increasingly important part of product growth strategies for pharmaceutical and biopharmaceutical companies. Biopharmaceutical products have rapidly taken over pharmaceutical company revenues, with sales of the top six antibody products viz., Humira, Remicade, Enbrel, Rituxan, Avastin, Herceptin, at just over USD 51 billion in 2015. 77% of over 900 biopharmaceutical products are produced in mammalian cell culture systems in the United States and Europe. In terms of production capacity, North America holds the greatest at 52%, followed by Europe and Asia. Due to government incentives in tax reforms, favorable locations with mature pipelines, and the ability to manage complex global supply chains, Asia has significant growth capacity. Samsung, Bristol-Myers Squibb, and Novartis are some of the key players in the market.

About the Geography

Hong Kong is a special administrative region of the People's Republic of China. It is the world’s freest and eighth largest economy. Hong Kong has no tariffs on imported goods and levies excise duty only on hydrocarbon oil, hard alcohol, tobacco, and methyl alcohol. It is the second largest recipient as well as supplier of FDI in the world. The country was ranked fifth easiest country to do business, by Doing Business.

Hong Kong acts as a bridgehead to China’s production, has an efficient banking system, favorable tax measures, excellent infrastructure, strong government, light legislations, well-educated skilled workers, and freedom of information. In 2003, Hong Kong SAR government launched CIES facilitated entry for foreign investors through investment into permissible assets, without the need to establish or join a business. Foreign companies can be set up freely, register their brands and the director of the company need not be a citizen or resident of Hong Kong. The only drawbacks are the high cost of living, elevated salaries, dependence on the financial sector, and exposure to global market risks.

With the presence of all major firms in the small region of Hong Kong, conducting business becomes very easy. Hong Kong is deemed to be the safest place to invest in the South-East Asia region.

The Market Entry Series

Exploring global markets is now recognized as the shortest way to ensure high time to efficiency conversion, when trying to expand revenues past domestic markets, for firms both large and small. Our market entry series, priced suitably low contains the essentials of all the parameters (Refer: Table of Contents) you must be apprised of before you can have a well informed contemplation of a business opportunity in your choice of industry, in your choice of geography.